Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses abstract S3-08,
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08,
Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy
Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02,
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05,
Advertisement
Advertisement
Jun
Today In Oncology23
Advertisement
